Efficacy assessment of highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotropin during pituitary suppression in patients undergoing GIFT for unexplained infertility

References

• Berger M. J., Taymor M. L. The role of luteinizing hormone in human follicular maturation and function. Am J Obstet Gynecol 1971; 111: 708–10
   PubMed Web of Science ®Google Scholar
• Edelstein M. C., Brzyski R. G., Jones G. S., et al. Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression. Fertil Steril 1990; 53: 103–6
   PubMed Web of Science ®Google Scholar
• Bomsel-Helmreich O., Vu N., Huyen L., et al. Effects of varying doses of HGC on the evolution of preovulatory rabbit follicles and oocytes. Hum Reprod 1989; 4: 636–42
   PubMed Web of Science ®Google Scholar
• Jacobs H. S., Porter R., Eshel A., . Prefertility uses of LHRH agonists analogues. LH RH and its Analogues: Contraception and Therapeutic Application, B. H. Vickery, I. J. Nestor, et al. MTP Press, Lancaster 1987; 303–19
   Google Scholar
• Chappel S. C., Howles C. Reevaluation of the role of luteinizing hormone and follicle stimulating hormone in the ovulatory process. Hum Reprod 1991; 6: 1206–12
   PubMed Web of Science ®Google Scholar
• Insler V., Potashnik G., Lunenfeld E., et al. The combined suppression/stimulation therapy in IVF—ET programmes: expectations and facts. Hum Reprod 1989; 4: 47–51
   PubMedGoogle Scholar
• Neveu S., Hedon B., Bringer J., et al. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilisation. Fertil Steril 1987; 47: 639–43
   PubMed Web of Science ®Google Scholar
• Bettendorf G., Braendle W., Lichtenberg V., et al. Pharmacologic hypogonadotropism — an advantage for gonadotrophin stimulation. Gynecol Endocrinol 1988; 2: 66
   Google Scholar
• Hughes E. G., Fedorkow D. M., Daya S., et al. The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intra-Fallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992; 8: 888–96
   Google Scholar
• Tan S. L., Maconochie N., Doyle P., et al. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotrophin-releasing hormone agonist buserelin. Am J Obstet Gynecol 1994; 71: 513–20
   Google Scholar
• Tarlatzis B. C., Pados G., Bontis J., et al. Ovarian stimulation with buserelin/hMG/hCG: prospective randomized study of short versus long protocol. Hum Reprod 1993; 8: 807–12
   PubMed Web of Science ®Google Scholar
• Homburg R., Armar A. N., Eshel A., et al. The influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovarian syndrome. Br Med J 1988; 297: 1024–6
   PubMed Web of Science ®Google Scholar
• Craft I., Brinsden P. Alternatives to IVF: the outcome of 1071 first GIFT procedures. Hum Reprod 1989; 4: 29–36
   PubMedGoogle Scholar
• Penzias A. S., Alper M. M., Oskowitz S. P., et al. Gamete intrafallopian transfer: assessment of the optimal number of oocytes to transfer. Fertil Steril 1991; 5: 311–13
   Google Scholar
• Hull M. GR, Joels L. A., Prosser C. J., et al. Experience using preparations of follicle stimulating hormone alone to stimulate the ovaries for assisted conception after pituitary desensitisation and simplified management of treatment. Horm Res 1995; 43: 230–7
   PubMedGoogle Scholar
• Fleming R., Coutts J. RT. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotrophin suppression. Fertil Steril 1986; 45: 226–30
   PubMed Web of Science ®Google Scholar
• Devroey P., Smitz J., van den Abbee I. E., et al. The use of LHRH analogues in IVF/GIFT/ZIFT programmes. Gynecol Endocrinol 1989; 3: 63–8
   PubMedGoogle Scholar
• Russel J. B., Lake Polan M., DeCherney A. H. The use of pure follicle-stimulating hormone for ovulation induction in normal ovulatory women in an in vitro fertilization program. Fertil Steril 1986; 45: 829–33
   PubMed Web of Science ®Google Scholar
• Diedrich K., Diedrich C., van der Ven H., et al. Ovarielle stimulation mit reinem FSH in einem In-vitro-Fertilisations-Programm. Geburshilfe Frauenheilkd 1987; 47: 612–18
   PubMedGoogle Scholar
• Daya S. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization: results of a meta-analysis. Horm Res 1995; 43: 224–9
   PubMedGoogle Scholar
• Devroey P., Tjandraprawira K., Mannaerts B., et al. A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization. Hum Reprod 1995; 10: 332–7
   PubMed Web of Science ®Google Scholar
• Torok A., Hamori M., Tinneberg H. R., et al. Comparison of the effects of hMG or pure FSH stimulation during suppression with an LHRH agonist analogue. Hum Reprod 1991; 6: 922–4
   PubMed Web of Science ®Google Scholar
• Duijkers I. JM, Vemer H. M., Hollanders J. MG, et al. Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation. Hum Reprod 1993; 8: 1387–91
   PubMed Web of Science ®Google Scholar
• Westergaard L. G., Erb K., Laursen S., et al. The effect of human menopausal gonadotrophin and highly purified urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Hum Reprod 1996; 11: 1209–13
   PubMed Web of Science ®Google Scholar
• Balasch J., Fabregues F., Creus M., et al. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotropin for ovarian stimulation after pituitary suppression in in-vitro fertilization. Hum Reprod 1996; 11: 2400–4
   PubMed Web of Science ®Google Scholar
• Messinis I. E., Templeton A., Baird D. T. Comparison between clomiphene plus pulsatile human menopausal gonadotropin and clomiphene plus pulsatile follicle stimulating hormone in induction of multiple follicular development in women. Hum Reprod 1986; 1: 223–6
   PubMed Web of Science ®Google Scholar
• Diczfalusy E., Harlin J. Clinical-pharmacological studies on human menopausal gonadotrophin. Hum Reprod 1988; 3: 21–7
   PubMed Web of Science ®Google Scholar
• Meldrum D. R., Tsao Z., Monroe S. E., et al. Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women. J Clin Endocrinol Metab 1984; 58: 755–7
   PubMed Web of Science ®Google Scholar
• Parinaud J., Oustry P., Perineau M., et al. Randomized trial of three luteinizing hormone releasing hormone analogues used for ovarian stimulation in an in vitro fertilization program. Fertil Steril 1992; 57: 1265–8
   PubMed Web of Science ®Google Scholar
• Tanbo T., Dale P. O., Kjekshus E., et al. Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome. Fertil Steril 1990; 53: 798–803
   PubMed Web of Science ®Google Scholar
• Hofmann G. E., Bentzien F., Bergh P. A. Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality. Fertil Steril 1993; 60: 675–9
   PubMed Web of Science ®Google Scholar
• Tarlatzis B. C., Grimbizis G., Pournaropoulos F., et al. The prognostic value of basal luteinizing hormone: follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques. Hum Reprod 1995; 10: 2545–9
   PubMed Web of Science ®Google Scholar